Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Bioorg Chem. 2018 Jan 10;77:144–151. doi: 10.1016/j.bioorg.2018.01.012

Evaluating hydrophobic galactonoamidines as transition state analogs for enzymatic β-galactoside hydrolysis

Jessica B Pickens 1, Logan G Mills 1, Feng Wang 1, Susanne Striegler 1,
PMCID: PMC5857253  NIHMSID: NIHMS943902  PMID: 29353731

Abstract

A spectroscopic examination of six galactonoamidines with inhibition constants and efficacy in the low nanomolar concentration range (Ki = 6–11 nM, IC50 =12–36 nM) suggested only two of them as putative transition state analogs for the hydrolysis of β-galactosides by β-galactosidase (A. oryzae). A rationale for the experimental results was elaborated using docking and molecular dynamics studies. An analysis of the combined observations reveals several common factors of the compounds suggested as transition state analogs (TSAs): the putative TSAs have a similar orientation in the active site; show conserved positioning of the glycon; display a large number of H-bond interactions toward the catalytically active amino acid residues via their glycon; and exhibit hydrophobic interactions at the outer rim of the active site with small changes of the position and orientation of their respective aglycons.

Keywords: Inhibitor, transition state analogs, galactonoamidines, β-galactosidase, molecular dynamics, hydrophobic loops

Graphical Abstract

graphic file with name nihms943902u1.jpg

1. Introduction

The ubiquity of glycosidases in biological systems and the complexity of manipulating the glycosidic bonds in oligosaccharides indicate a need for evaluating mechanistic details of specific glycosidases.[1] These enzymes cleave glycosidic bonds either by retention or inversion of the configuration at the anomeric carbon atom of a glycoside substrate in a SN1 or SN2-like manner.[24] Both mechanisms go through oxocarbenium ion-like transition states during the substrate hydrolyses.[2] As β-galactosidases are prominent in many diseases, [57] a detailed knowledge of their mechanistic function is advantageous.

A common strategy toward this goal relies on the design of inhibitors possessing currently known features of the transition states of glycoside hydrolyses. The derived compounds often display an oxocarbenium ion-like feature with a flattened half-chair conformation and a sp2-like character at the anomeric center.[8] Additionally, a positive charge at the location of the ring oxygen atom was found to be important.[9] Lastly, spacers between glycon and aglycon of the inhibitors were designed to mimic the lengthening of the glycosidic bond during cleavage.[9, 10] The transition states of enzymatic reactions have been examined by various techniques including studies based on spectroscopic evaluations, [11] kinetic isotope effects, [12] X-ray diffraction, [13, 14] and mutations of residues within the active sites[15] in combination with molecular dynamics simulations.[16] In the absence of crystallographic data, an in-depth evaluation of the corresponding enzymes by a combination of spectroscopic and molecular modeling studies is often used to provide mechanistic insights for the development of new drugs in future therapeutic treatments.[1721]

In this context, we previously synthesized a small library of 7 galactonoamidines and evaluated their ability to inhibit β-galactosidase (A. oryzae).[22] The compounds inhibit the selected β-galactosidase competitively and show low nanomolar inhibition constants (Ki = 8–60 nM).[22] However, only p-methylbenzyl galactonoamidine (1a) was characterized as a putative transition state analog using experimental methods described by Bartlett et al.[23, 24] It is hypothesized that the nature of the aglycon of the respective galactonoamidine is responsible for the decisive differences in the stabilization of the transition state during enzymatic glycoside hydrolysis. This hypothesis prompted a detailed structure-activity relationship study after extending the library to 25 galactonoamidines while installing aglycons that support hydrophobic, hydrophilic, π-π stacking and H-bond donor or acceptor interactions.[18, 25] Although all members in the library were classified as competitive inhibitors with inhibition constants in the nanomolar concentration range, [26] only six of those amidines (1b–g) displayed inhibition constants below 15 nM and IC50 values below 36 nM similar to 1a (Chart 1).

Chart 1.

Chart 1

Structures of galactonoamidines 1a–g

The respective aglycons of the six inhibitors encompass a large structural variety that includes aromatic residues with extended spacer (1b), cyclic aliphatic moieties with cycloheptyl (1c) or cyclohexyl (1d) rings, a branched aliphatic 2-ethylhexyl residue (1e), a very small cyclopropyl group (1f) and a linear aliphatic heptyl chain (1g). The noted similarities in inhibition efficacy and inhibition constants, despite the structural diversity of the aglycons, prompted our interest in an in-depth evaluation of the selected galactonoamidines as putative transition state analogs of the enzymatic glycoside hydrolysis by β-galactosidase (A. oryzae). Our results from the spectroscopic investigation of the inhibitor interactions in the active site of the selected enzyme, related docking studies, and subsequent molecular dynamic analyses are summarized below.

2. Results and discussion

2.1. Molecular docking study

Prior to extensive experimental evaluation of inhibitors as putative transition state analogs (TSAs), Autodock Vina was used for an initial estimate of docked inhibitor-enzyme assemblies. The structure of β-galactosidase (A. oryzae, 4IUG) is known from X-ray diffraction studies.[27] Its active site encompasses residues of 8 amino acids, including catalytically active Glu200 (proton donor) and Glu298 (nucleophile) (Figure 1).[27]

Figure 1.

Figure 1

Amino acids of β-galactosidase (A. oryzae) comprising the active site and part of the hydrophobic loops at its outer rim (margenta).[27]

The docked inhibitor-enzyme assemblies were examined for their H-bonding interactions, and for the orientation of the galactonoamidines within the active site. Particular scrutiny was paid to the interactions of 1a–g with the residues of the two catalytically active amino acids. The predicted free energies of all docked conformations of the enzyme-amidine assemblies vary by 1.7 kcal/mol or less confirming the noted similarity of the experimentally determined inhibition ability of 1a–g.

The docking study suggest H-bonding interactions of the inhibitors with both catalytically active amino acid residues and Ala141 (Table 1). The inhibitors may act as a H-bond acceptor toward Asn199, Tyr96, and Tyr342, and as a H-bond donor toward the catalytically active amino acid residues and Glu142. The position of the glycon moiety in the docked inhibitor-protein assemblies seems conserved.

Table 1.

Binding free energies ΔG (kcal/mol) and H-bonding interactions via the glycon of galactonoamidines 1a–f and amino acid residues in the active site of β-galactosidase (A. oryzae).

Entry Compound ΔG (kcal/mol) H-bond interactions involving
OH (C-2) OH (C-3) OH (C-4) OH (C-6) NH (endocyclic) NH (exocyclic)
1 1a −7.5 E142 E298 A141, Y342 E200 -
2 1b −7.4 E142 E298 A141, E142 N199 E200 E200
3 1c −7.4 - - A141, Y342 E298, N199 E200 E200
4 1d −7.2 - E298 A141 N199, Y96 E200 E200
5 1e −6.6 - E298 A141, Y342 E298, N199 E200 E200
6 1f −6.3 - E298 A141 E298, N199 E200 -
7 1g −5.8 - E298 A141, Y342 E298, N199 E200 E200

By contrast, remarkable differences in the orientation of the aglycon moieties in the docked inhibitor-enzyme assemblies were observed upon examination of interactions between 1a–g and amino acid residues at the outer rim of the active site (Ala237, Leu262, Phe264, Phe304, and Trp806). The important role of such hydrophobic interactions for the stabilization of substrates during catalytic turnover was recently disclosed in a crystallographic study using β-galactosidase (A. niger) from the same family of glycoside hydrolases.[15]

Here, the hydrophobic residues create a tunnel-like binding pocket around the aglycons of 1a–g. As galactonoamidine 1a was previously classified as a TSA, the planar orientation of its methylbenzyl aglycon was used as a standard. The aglycons of amidines 1b and 1d are slightly tilted out of a plane formed by the aglycon of 1a. [28] The cycloheptyl and cyclopropyl aglycons of amidines 1c and 1e show large deviations in their orientation relative to 1a. The aliphatic branched and linear aliphatic residues in amidines 1e and 1g appear in a perpendicular orientation relative to the aglycon in 1a (Figure 2a–f).

Figure 2.

Figure 2

Galactonoamidines 1b–g (blue) docked in the active site of β-galactosidase (A. oryzae, 4IUG) and depicted relative to 1a (yellow) are shown in two different perspectives (a) 1b, (b) 1c, (c) 1d, (d) 1e, (e) 1f, and (f) 1g; residues of catalytically active amino acids (Glu298 and Glu200) in green, all others in grey; H-bonding interactions between the proton donor (Glu200) and 1b–g at the endocyclic NH group (green) and the exocyclic NH group (dark cyan).

The docking study indicates for all inhibitors a large number of conserved H-bonding interactions with amino acids in the active site. The orientation of the glycon is conserved, while the orientation of the aglycons is influenced by interactions with hydrophobic amino acid residues at the outer rim of the active site. High similarity of the galactonoamidine orientation in protein-inhibitor assemblies are noted for 1a, 1b and 1d. However, further insights for classification of a compound as a putative TSA were obtained by spectroscopic evaluation of the inhibitors with binding energies within 1.2 kcal/mol relative to 1a (i.e. 1e–f), and followed by molecular dynamics simulations.

3. Spectroscopic evaluation of galactonoamidines as putative transition state analogs

Following a spectroscopic method introduced by Bartlett et al. for the characterization of competitive inhibitors as putative transition state analogs based on Eyrings’ transition state theory, [23, 29] we evaluated the selected galactonoamidines 1b–f. The enzyme-catalyzed hydrolysis of nine structurally related nitrophenyl-β-D-galactopyranoside substrates 2a–i was monitored by UV/Vis spectroscopy in presence and absence of 1b–f (Scheme 1).

Scheme 1.

Scheme 1

Enzymatic hydrolysis of model substrates 2a–i in the presence of galactonoamidines 1b–f in 50 mM acetate buffer at pH 5.00, 30.0 ± 0.1 °C.

The galactonoamidines were used in a 0.25–1 mM concentration range. The determined inhibition constants (Ki) are given as an average of independent experiments using three or more different inhibitor concentrations (Table 2). Nanomolar inhibition constants (Ki = 6–170 nM) were observed for the enzymatic hydrolysis of all substrates in the presence of 1b–f.

Table 2.

Inhibition constants (Ki) for the enzymatic hydrolysis of nitrophenyl-β-D-galactopyranosides 2a–i in the presence of galactonoamidines 1b–f in 50 mM acetate buffer at pH 5.00 and 30.0 ± 0.1 °C.

Entry S kcat/KM × 106 [min−1M−1][25] Ki [nM] [1b] Ki [nM] [1c] Ki [nM] [1d] Ki [nM] [1e] Ki [nM] [1f]
1 2a 3.61 17.4 30.4 24.2 28.6 35.8
2 2b 3.23 11.1 42.8 20.3 20.8 37.9
3 2c 3.76 13.5 13.3 20.5 31.9 29.7
4 2d 4.31 11.8 39.2 20.1 26.5 14.6
5 2e 2.18 21.2 135 35.5 81.5 30.6
6 2f 9.86 60.7 168 87.5 145 64.9
7 2g 3.85 15.7 61.8 16.2 40.2 35.2
8 2h 3.99 14.2 40.6 18.7 36.7 51.5
9 2i 3.59 8.6 [25] 6.3 [25] 11.3 [25] 7.8 [25] 9.5 [25]

Subsequently, the determined inhibition constants (Ki) were correlated to the catalytic efficiency (kcat/KM) of the enzymatically catalyzed substrate hydrolysis in absence of inhibitors (Figure 3). The evaluation of correlation coefficients and standard deviations for a linear fit of the data in double logarithmic plots results in an estimate of the ability of the inhibitors to function as a TSA of the catalyzed glycoside hydrolysis.[23] Ideally, a linear fit of the data with a slope of 1, and a standard deviation factor R2 of 1 is expected.[23] Deviations from this ideal exclude the compound under investigation from further consideration as a putative TSA.[23] Given the criteria introduced above, galactonoamidines 1b and 1d qualify as putative TSAs for the hydrolysis of β-galactosides by β-galactosidase (A. oryzae) (Figure 3a), while all other amidines 1c and 1e–f are very potent competitive inhibitors that do not fully resemble the features of the transition state of the reaction (Figure 3b).

Figure 3.

Figure 3

Double-logarithmic plot of the inhibition constant (Ki) and the catalytic efficiency (kcat/KM) for the hydrolysis of nitrophenyl-β-D-galactopyranosides 2a–i with linear fit in the presence of (a); 1b ( Inline graphic) a = 1.02 ± 0.10, R2 = 0.93; and 1d ( Inline graphic) a = 1.08 ± 0.10, R2 = 0.95; and (b) 1c ( Inline graphic) a = 1.17 ± 0.32, R2 = 0.69; 1e ( Inline graphic) a = 1.16 ± 0.21, R2 = 0.83; 1f ( Inline graphic) a = 0.44 ± 0.19, R2 = 0.46;

Interestingly, the experimental selection of amidines (1a, 1b and 1d) with putative transition state-like character is identical to those suggested by molecular docking studies (see above). Their docked inhibitor-protein conformations show the aglycon in a hydrophobic tunnel-like loop that is formed by several amino acids at the outer rim of the active side. In order to further illuminate the underlying stabilizing forces for the inhibitor-protein assemblies, molecular dynamics simulations were employed.[30]

4. Molecular dynamic studies of galactonoamidine-protein interactions

The interactions between the galactonoamidines 1af and amino acids within and outside of the active site of β-galactosidase (A. oryzae, 4IUG) were further examined by molecular dynamics simulations employing the GROMOS 96-43A1 model.[30] Similar investigations to describe assemblies between enzymes and carbohydrate analogs were reported by others recently.[31, 32] Interactions of an inhibitor with both catalytically active amino acid residues within the active site were previously suggested as a prerequisite for the designation of the compound as a TSA.[33] Along these lines, the probability of H-bond formation between the hydroxyl groups of the glycons of galactonoamidines 1af and all amino acid residues within the active site was examined with an focus on H-bond interactions toward the catalytically active amino acid residues Glu298 (nucleophile) and Glu200 (donor) (Figures 4a and b).

Figure 4.

Figure 4

(a) Probability of the overall number of H-bond interactions between 1a–f and β-galactosidase (A. oryzae); (b) occupancy of the catalytic amino acid residues Glu298 (nucleophile) and Glu200 (donor) with 1a–f

The amidines 1ab and 1de show higher probability to form an overall larger number of H-bond interactions within the active site than inhibitors 1c and 1f (Figure 4a). Over most of the simulation time, all galactonoamidines display high probability for H-bond formation with catalytically active residue Glu298 (Figure 4b). Similar interactions with Glu200 were noted for amidines 1ad, but not for 1ef. The molecular dynamics simulations further indicate almost identical orientations of the glycon moieties of the inhibitors of 1a, 1b and 1d in the active site (RMSD ≤ 0.65 Å).

The combined observations of the modeling study support considerations of amidines 1ad as transition state analogs, while rendering the selection of 1ef unlikely. Further insights were then obtained by comparing simulations of the protein in the absence and presence of galactonoamidines 1af, focusing on the orientation and location of their respective aglycon in the active site (Figure 5).

Figure 5.

Figure 5

Overlay of simulated structures of β-galactosidase (A. oryzae) in presence (grey) and absence (purple) of galactonoamidine 1a (orange).

The simulations disclose the presence of a triangular hydrophobic tunnel and its induced fit movement upon binding of 1a, 1b and 1d in the active site. The hydrophobic tunnel encompasses Ala237, Leu262, Phe264, and Trp806 at the outer rim of the active site as revealed by the rigid docking study, and extends into a hydrophobic loop comprised of Pro261, Phe278, Phe281, Ala301, Ala303, Phe304, Ala317, Val319, and Met343 upon relaxation with molecular dynamics.

During the simulation, the aglycon of 1a orients itself via the p-methyl substitutent toward several residues of the hydrophobic tunnel (Ala237, Pro261, Leu262, Phe264, Pro278 and Phe281) (Figure 6a). Likewise, the flexibility of the extended spacer of the aglycon in 1b allows the inhibitor to adapt a conformation that provides proximity of the propylene spacer to hydrophobic residues (Ala237, Pro261, Leu262, Phe264, Ala301, Ala303, Phe304, Ala317, Val319, Met343, and Trp806) at the outer rim of the active site (Figure 6b). Similar hydrophobic interactions for the cyclohexyl aglycon of 1d are noted and accompanied by an induced fit movement of the respective hydrophobic residues as well (Figure 6d). Lastly, π-π stacking interactions to support inhibitor binding are not apparent, and were therefore excluded from any further consideration as means of inhibitor stabilization in the active site of β-galactosidase (A. oryzae).

Figure 6.

Figure 6

Orientation of galactonoamidines within the active sites of β-galactosidase (A. oryzae) as predicted with molecular dynamic simulations; (a) 1a (b) 1b (c) 1c, (d) 1d (e) 1e; and (f) 1f.

By contrast, galactonoamidines 1c, 1e and 1f (Figure 5c–e, f) interact differently in the active site of β-galactosidase (A. oryzae). Over the 30 ns simulation time, larger conformational fluctuations of glycon and aglycon of these inhibitors in location and orientation were noted that indicate overall weaker binding interactions. While the aglycons from 1c, 1e and 1f could support hydrophobic binding interactions, the simulation indicates their perpendicular orientation away from the hydrophobic tunnel. An induced fit upon binding of 1c, 1e and 1f in the active site and accompanying movement of the hydrophobic tunnel is not apparent. The combined observations are in line with the experimental evaluation described above, that disclosed a very poor correlation between inhibition constant and catalytic efficiency for 1c, ef (→Figure 2b), and suggest to exclude those amidines from further consideration as TSAs.

5. Conclusion

A previously synthesized library of 25 galactonoamidines contains 7 potent galactonoamidines 1a–g with inhibition constants below 15 nM and IC50 values between 12–36 nM.[25] Amidine 1a was then experimentally characterized as a TSA by spectroscopic analysis, and hydrophobic interactions within the active site were suggested as source for its proficiency.[26] All other amidines 1b–g under investigation here contain aglycons in a large structural variety encompassing aliphatic linear, branched or cyclic moieties as well as aromatic groups. Despite their apparent structural diversity, the noted similarities in inhibition constants and efficacy of galactonoamidines 1a–g prompted our interest in an in-depth evaluation of the underlying forces to discriminate potent competitive inhibitors from putative TSAs of the enzymatic glycoside hydrolysis by β-galactosidase (A. oryzae).

The spectroscopic evaluation identified amidines 1a, 1b and 1d as putative TSAs, which is consistent with computational investigations based on a combination of interactions. Most importantly, the study disclosed an induced fit movement of the enzyme upon interaction with amidines 1a, 1b and 1d that is not apparent for all others. Thereby, a loop encompassing an array of hydrophobic amino acids at the outer rim of the active site is suggested to sustain hydrophobic interaction with the identified amidines over their aglycons. Additionally, amidines 1a, 1b and 1d show a high probability for interactions with both catalytically active amino acid residues, an almost conserved orientation of their glycon in the active site, and similar orientation of their aglycons over the simulation time. All other inhibitors lack support upon interaction in the active site by a similar combination of interactions. Evidence for π-π stacking interactions through aromatic residues was not obtained experimentally or by molecular dynamics simulations for any amidine. The study overall identified hydrophobic interactions and induced fit movements of β-galactosidase (A. oryzae) as a decisive driving force for interactions with TSA-like inhibitors and will further support ongoing efforts for the design of potent glycosidase inhibitors.

6. Experimental Section

6.1. Instrumentation

The FilterMax F5 Multi-Mode Microplate reader (Molecular Devices) was employed for all kinetic assays based on UV/Vis spectroscopy using flat bottom transparent 96-well plates (Bio- Greiner One). All pH values were obtained using a Φ 250 pH meter (Beckman) equipped with a refillable ROSS combination pH electrode (Orion) with an 8 mm semi-micro tip and epoxy body. The pH meter was calibrated using standard buffers prior to use. Nanopure water at a resistance of 18.2 MΩ.cm was obtained from a water purification system (ThermoScientific Barnstead E-pure).

6.2. Materials

Acetic acid at 99.7% purity was obtained from VWR. β-galactosidase (A. oryzae) and sodium hydroxide at 99.999% purity were obtained from Sigma-Aldrich. The enzyme was received as a lyophilized powder stabilized with dextrin and stored at −18 °C prior to use. Previous BCA assays confirmed a protein content of 10 %.[34] The molar weight was determined as 86,800 g mol−1.[34] The galactonoamidine inhibitors 1a–g and the nitrophenyl-β-D-galactopyranoside substrates 2a–i were synthesized as described.[25, 26]

6.3. Spectroscopic evaluation of galactonoamidines as TSAs

6.3.1. Acetate buffer

Typically, a 500 mL aliquot of a 50 mM acetate buffer at pH 5.00 was prepared using standard methods at ambient temperature accounting for use at 30° C. The buffer was stored at ambient temperature and used within 10 days or discarded.

6.3.2. Stock solution of β-galactosidase (A. oryzae)

Typically, 4.5 mg of lyophilized β-galactosidase (A. oryzae) were dissolved in 5 mL of buffer solution. A 500 μL aliquot was further diluted into 10 mL with the same buffer yielding a 518 nM enzyme stock solution that was stored on ice until use.

6.3.3. Stock solutions of nitrophenyl-β-D-galactopyranoside substrates 2a–i

Typically, 7–11 mg of the respective nitrophenyl-β-D-galactopyranosides 2a–i were dissolved in 5 mL of acetate buffer. The resulting solution was kept at ambient temperature and used within 4 hr of preparation.

6.3.4. Stock solutions for galactonoamidine inhibitors 1b–f

5 mL of 0.25, 0.50, 0.75 and 1.0 μM solutions of inhibitors 1b–f were a prepared by serial dilution of appropriate volumes of 1 mM solutions in nanopure water. The resulting four stock solutions were kept at ambient temperature until use.

6.3.5. Kinetic assay

Initially, 0–70 μL of the substrate stock solution was added in 10 μL increments in 96-well plates. A constant 10 μL aliquot of the inhibitor stock solution and appropriate amounts of buffer solution were added to keep the volume in each well at 80 μL. After equilibration at 30°C, a 20 μL aliquot of the enzyme stock solution was added to initiate the glycoside hydrolysis. The change in absorbance due to product formation was followed at 405 nm over 15 min in 27s intervals for a total of 34 readings.

6.3.6. Data analysis

The absorbance data were initially transferred into product concentrations using previously determined apparent extinction coefficients.[24] The change in product concentration was then plotted over time, and the initial rates were determined by linear regression of the resulting data. A plot of respective rates corrected for enzyme concentration versus substrate concentration yielded hyperbolic data. The Michaelis-Menten model was applied to determine the catalytic rate constant and the apparent binding affinity for each substrate in absence (kcat, KM) and presence (k’cat, K’M) of inhibitors 1b–f using non-linear regression.[35] The inhibition constants (Ki) were then determined from the kinetic parameters using equation (1)

Ki=KM[I]KM-KM (1)

The kinetic parameters were determined in triplicate, and the given inhibition constants are reported as an average of data obtained from 3–4 different inhibitor concentrations.

6.4. Docking studies

The structure of β-galactosidase (A. oryzae, 4IUG) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/).[36] The structures of galactonoamidines 1a–g were minimized using an MM2 force field and converted from a mol file to a pdb file using PYMOL. The pdb files were then imported into the PMV-1.5.6 software[37] and converted into pdbqt files while allowing all non-ring bonds to rotate. All water molecules, solvents, and substrates were removed from the enzyme structure file prior to the docking study. The coordinates of the enzyme were transferred from pdb into pdbqt files with the addition of Kollman partial charges on all atoms, polar H-atoms were added to all residues using AutoDock Vina Tools.[38] A 30×30×30 A3 grid box was then placed at the center of the active site of the β-galactosidase. The exhaustiveness was set to 100 to account for the size of the grid box, while all other parameters were set to defaults of the AutoDock Vina 1.1.2 Software. The calculations yielded nine conformations that were scored based on their binding affinity in kcal/mol. The docked inhibitor-enzyme assembly with the lowest free energy estimate was selected for further investigation.

6.5. Molecular dynamic studies

Molecular dynamic simulations for the galactonoamidines 1a–f in complex with β-galactosidase (A. oryzae) were performed with GROMACS 4.6.7 software using the GROMOS96 43A1 force field. [39] The coordinate and topology files of the enzyme were generated with the pdb2gmx program.[30] The lowest free energy conformation of each docked inhibitor was imported into PRODRG 2.5 software also using the GROMOS96 43A1 model.[40, 41] Point charges assigned by the PRODRG program may not conform with those of the 43A1 force field, and were consequently corrected.[41] The inhibitor-protein assemblies were prepared by adding coordinates and topology files of 1a–f to those of β-galactosidase (A. oryzae). The resulting protein-inhibitor complexes were then solvated in a 2389 nm3 cubic box with 75,211–75,214 water molecules described by the simple point charge (SPC) water model.[42] Last, 28 randomly selected water molecules were replaced by sodium ions to neutralize the system.

The neutralized systems were minimized using the steepest-decent protocol to avoid any steric clashes.[30] Using a stochastic scaling thermostat, a NVT simulation over 100 ps was done at experimental conditions (303K), and followed by a NPT simulation at 1 bar over 500 ps.[43]. Finally, 31 ns NPT simulations were carried out using the Nosé-Hoover thermostat[44] and the Parrinello-Rahman barostat[45] with a thermostat relaxation time constant of 2.0 ps and a barostat relaxation time constant of 5.0 ps.. The last 30 ns of the NPT simulation were treated as production. All molecular dynamics simulations were performed using an integration time step of a 2 fs with a particle mesh Ewald treatment for coulombic interactions. Additional details of the molecular dynamics protocol have been described previously.[46]

Supplementary Material

1
Download video file (25.4MB, mp4)
2
Download video file (25.4MB, mp4)
3
Download video file (25.4MB, mp4)
4
Download video file (25.4MB, mp4)
5
Download video file (23MB, mp4)
6
Download video file (33.3MB, mp4)

Highlights.

  • Spectroscopic identification of inhibitors as transition state analogs (TSAs)

  • Molecular dynamics studies reveal key features of TSA characteristics

  • Hydrophobic loop stabilizes aglycon during enzymatic glycoside hydrolysis

Acknowledgments

Support of this research to F. W. by the National Institutes of Health (1R01GM120578), to S.S. from the National Science Foundation (CHE-1305543) and the Arkansas Biosciences Institute, and to L.G.M by a Statewide Undergraduate Research Fellowship from the Arkansas Department of Higher Education and an Undergraduate Research Fellowship from the University of Arkansas Honors College are gratefully acknowledged. The facilities used in this study were supported by Grant Number P30 GM103450 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH). The molecular dynamic simulations were performed in the Arkansas High-Performance Computing Center, which is supported by the National Science Foundation (ACI0722625, ACI0959124, ACI0963249, and ACI0918970) and the Division of Science and Technology at the Arkansas Economic Development Commission.

Footnotes

Declaration of interests: none

Supplementary Information:

Supplementary data for all molecular docking and molecular dynamic simulations between 1a–f and β-galactosidase (A. oryzae, 4IUG) can be found online at doi:10.1016/j.carres.2017.xx.xx. including output files from AutoDock Vina, input files for molecular dynamic studies, and movies visualizing the results of all simulations over 30 ns.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References and notes

  • 1.Henrissat B. Biochem J. 1991;280:309–316. doi: 10.1042/bj2800309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sinnott ML. Chem Rev. 1990;90:1171–1202. [Google Scholar]
  • 3.Bohe L, Crich D. Nat Chem. 2016;8:99–100. doi: 10.1038/nchem.2436. [DOI] [PubMed] [Google Scholar]
  • 4.Martin A, Arda A, DJ, Martin Mingot A, Probst N, Sinaÿ P, Jiménez Barbero J, Thibaudeau S, Blériot Y. Nat Chem. 2016;8:186–191. doi: 10.1038/nchem.2399. [DOI] [PubMed] [Google Scholar]
  • 5.Magini A, Polchi A, Tozzi A, Tancini B, Tantucci M, Urbanelli L, Borsello T, Calabresi P, Emiliani C. Int J Biochem Cell Biol. 2015;58:62–70. doi: 10.1016/j.biocel.2014.11.001. [DOI] [PubMed] [Google Scholar]
  • 6.Caciotti A, Garman SC, Rivera-Colón Y, Procopio E, Catarzi S, Ferri L, Guido C, Martelli P, Parini R, Antuzzi D, Battini R, Sibilio M, Simonati A, Fontana E, Salviati A, Akinci G, Cereda C, Dionisi-Vici C, Deodato F, d’Amico A, d’Azzo A, Bertini E, Filocamo M, Scarpa M, di Rocco M, Tifft CJ, Ciani F, Gasperini S, Pasquini E, Guerrini R, Donati MA, Morrone A. Biochim Biophys Acta. 2011;1812:782–790. doi: 10.1016/j.bbadis.2011.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bradbury AM, Gray-Edwards HL, Shirley JL, McCurdy V, Colaco AN, Randle AN, Christopherson PW, Bird AC, Johnson AK, Wilson DU, Hudson JA, De Poma NL, Sorjonen DC, Brunson BL, Jeyakumar M, Platt FM, Baker HJ, Cox NR, Sean-Esteves M, Martin DR. Exp Neurol. 2015;263:102–112. doi: 10.1016/j.expneurol.2014.09.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Panday N, Canac Y, Vasella A. Helvet Chim Acta. 2000;83:58–79. [Google Scholar]
  • 9.Papandreou G, Tong M, Ganem B. J Am Chem Soc. 1993;115:11682–11690. [Google Scholar]
  • 10.Shanmugasundaram B, Vasella A. Helvet Chim Acta. 2005;88:2593–2602. [Google Scholar]
  • 11.Martin A, Arda A, Désiré J, Martin-Mingot A, Probst N, Sinaÿ P, Jiménez-Barbero J, Thibaudeau S, Blériot Y. Nat Chem. 2016;8:186. doi: 10.1038/nchem.2399. [DOI] [PubMed] [Google Scholar]
  • 12.Bennet AJ, Sinnott ML. J Am Chem Soc. 1986;108:7287–7294. [Google Scholar]
  • 13.Zechel DL, Boraston AB, Gloster T, Boraston CM, Macdonald JM, Tilbrook DMG, Stick RV, Davies GJ. J Am Chem Soc. 2003;125:14313–14323. doi: 10.1021/ja036833h. [DOI] [PubMed] [Google Scholar]
  • 14.Wheatley RW, Huber RE. Biochem Cell Biol. 2015;93:531–540. doi: 10.1139/bcb-2015-0037. [DOI] [PubMed] [Google Scholar]
  • 15.Rico-Díaz A, Ramírez-Escudero M, Vizoso-Vázquez Á, Cerdán ME, Becerra M, Sanz-Aparicio J. FEBS J. 2017;284:1815–1829. doi: 10.1111/febs.14083. [DOI] [PubMed] [Google Scholar]
  • 16.Sabini E, Wilson KS, Danielsen S, Schuelein M, Davies GJ. Acta Crystallogr D. 2001;57:1344–1347. doi: 10.1107/s0907444901010873. [DOI] [PubMed] [Google Scholar]
  • 17.Asano N, Kizu H, Oseki K, Tomioka E, Matsui K, Okamoto M, Baba M. J Med Chem. 1995;38 doi: 10.1021/jm00013a012. [DOI] [PubMed] [Google Scholar]
  • 18.Artola M, Wu L, Ferraz MJ, Kuo CL, Raich L, Breen IZ, Offen WA, Codée JD, van der Marel GA, Rovira C. ACS Cent Sci. 2017;3:784–793. doi: 10.1021/acscentsci.7b00214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Beenakker TJ, Wander DP, Offen WA, Artola M, Raich L, Ferraz MJ, Li KY, Houben JH, van Rijssel ER, Hansen T. J Am Chem Soc. 2017;139:6534–6537. doi: 10.1021/jacs.7b01773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kawatkar SP, Kuntz DA, Woods RJ, Rose DR, Boons GJ. J Am Chem Soc. 2006;128:8310–8319. doi: 10.1021/ja061216p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Motley MW, Schramm VL, Schwartz SD. J Phys Chem B. 2013;117:9591–9597. doi: 10.1021/jp4030443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kanso R, Striegler S. Carbohydr Res. 2011;346:897–904. doi: 10.1016/j.carres.2011.02.021. [DOI] [PubMed] [Google Scholar]
  • 23.Bartlett PA, Marlowe CK. Biochemistry. 1983;22:4618–4624. doi: 10.1021/bi00289a002. [DOI] [PubMed] [Google Scholar]
  • 24.Fan QH, Striegler S, Langston RG, Barnett JD. Org Biomol Chem. 2014;12:2792–2800. doi: 10.1039/c4ob00153b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Fan QH, Claunch KA, Striegler S. J Med Chem. 2014;57:8999–9009. doi: 10.1021/jm501111y. [DOI] [PubMed] [Google Scholar]
  • 26.Fan QH, Striegler S, Langston RG, Barnett JD. Org Biomol Chem. 2014;12:2792–2800. doi: 10.1039/c4ob00153b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Maksimainen MM, Lampio A, Mertanen M, Turunen O, Rouvinen J. Int J Biol Macromolec. 2013;60:109–115. doi: 10.1016/j.ijbiomac.2013.05.003. [DOI] [PubMed] [Google Scholar]
  • 28.Angles for the deviation of the aglycon relative to 1a are 25.1° (1b), 28.8° (1d), 82.2° (1c), 114.8° (1e), 75.8° (1f) and 118.2 1g
  • 29.Eyring H. J Chem Phys. 1935;3:107–115. [Google Scholar]
  • 30.Scott WR, Hünenberger PH, Tironi IG, Mark AE, Billeter SR, Fennen J, Torda AE, Huber T, Krüger P, van Gunsteren WF. J Phys Chem A. 1999;103:3596–3607. [Google Scholar]
  • 31.Cagir A, Tao ZF, Sucheck SJ, Hecht SM. Bioorg Med Chem. 2003;11:5179–5187. doi: 10.1016/j.bmc.2003.08.033. [DOI] [PubMed] [Google Scholar]
  • 32.Ibrahim DA, Boucau J, Lajiness DH, Veleti SK, Trabbic KR, Adams SS, Ronning DR, Sucheck SJ. Bioconjug Chem. 2012;23:2403–2416. doi: 10.1021/bc3004342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pickens JB, Striegler S, Fan QH. Bioorg Med Chem. 2016;24:3371–3377. doi: 10.1016/j.bmc.2016.04.069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kanso R, Yancey EA, Striegler S. Tetrahedron. 2012;68:47–52. [Google Scholar]
  • 35.Leatherbarrow RJ. Trends Biochem Sci. 1990;15:455–458. doi: 10.1016/0968-0004(90)90295-m. [DOI] [PubMed] [Google Scholar]
  • 36.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. Nucleic Acids Res. 2000;28:235–242. doi: 10.1093/nar/28.1.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sanner MF. J Mol Graphics Mod. 1999;17:305–320. [PubMed] [Google Scholar]
  • 38.Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodwill DS, Olson AJ. J Comput Chem. 2009;30:2785–2791. doi: 10.1002/jcc.21256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hess B, Kutzner C, Van Der Spoel D, Lindahl E. J Chem Theory Comput. 2008;4:435–447. doi: 10.1021/ct700301q. [DOI] [PubMed] [Google Scholar]
  • 40.Schuttelkopf AW, van Aalten DMF. Acta Crystallogr D. 2004;60:1355–1363. doi: 10.1107/S0907444904011679. [DOI] [PubMed] [Google Scholar]
  • 41.Lemkul JA, Allen WJ, Bevan DR. J Chem Inf Model. 2010;50:2221–2235. doi: 10.1021/ci100335w. [DOI] [PubMed] [Google Scholar]
  • 42.Berendsen H, Grigera J, Straatsma T. J Phys Chem. 1987;91:6269–6271. [Google Scholar]
  • 43.Bussi G, Donadio D, Parrinello M. J Chem Phys. 2007;126:014101. doi: 10.1063/1.2408420. [DOI] [PubMed] [Google Scholar]
  • 44.Nose S. J Phys Condens Matter. 1990;2:SA115. [Google Scholar]
  • 45.Ray JR, Rahman A. J Chem Phys. 1984;80:4423–4428. [Google Scholar]
  • 46.Pickens JB, Wang F, Striegler S. Biomol Med Chem. 2017 doi: 10.1016/j.bmc.2017.07.020. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
Download video file (25.4MB, mp4)
2
Download video file (25.4MB, mp4)
3
Download video file (25.4MB, mp4)
4
Download video file (25.4MB, mp4)
5
Download video file (23MB, mp4)
6
Download video file (33.3MB, mp4)

RESOURCES